SE0101675D0 - Novel composition - Google Patents
Novel compositionInfo
- Publication number
- SE0101675D0 SE0101675D0 SE0101675A SE0101675A SE0101675D0 SE 0101675 D0 SE0101675 D0 SE 0101675D0 SE 0101675 A SE0101675 A SE 0101675A SE 0101675 A SE0101675 A SE 0101675A SE 0101675 D0 SE0101675 D0 SE 0101675D0
- Authority
- SE
- Sweden
- Prior art keywords
- novel composition
- methods
- pharmaceutical compositions
- relates
- present
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
- C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
Priority Applications (26)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE0101675A SE0101675D0 (sv) | 2001-05-11 | 2001-05-11 | Novel composition |
ARP020101633A AR037489A1 (es) | 2001-05-11 | 2002-05-03 | Quinolinas sustituidas y proceso para su preparacion |
CNB02809722XA CN1286815C (zh) | 2001-05-11 | 2002-05-06 | 4-苯胺基喹啉-3-甲酰胺类化合物 |
EEP200300544A EE200300544A (et) | 2001-05-11 | 2002-05-06 | 4-anilinokinoliin-3-karboksamiidid, nende kasutamine ning valmistamine |
PL02366766A PL366766A1 (en) | 2001-05-11 | 2002-05-06 | Novel 4-anilinoquinoline-3-carboxamides |
BR0209431-2A BR0209431A (pt) | 2001-05-11 | 2002-05-06 | Novos compostos de 4-anilinoquinolino-3-carboxamidas |
MXPA03010207A MXPA03010207A (es) | 2001-05-11 | 2002-05-06 | Nuevas 4-anilinoquinolin-3-carboxamidas. |
HU0401339A HUP0401339A2 (hu) | 2001-05-11 | 2002-05-06 | Új 4-anilino-3-kinolinkarboxamidok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények |
EP02733657A EP1387830A1 (en) | 2001-05-11 | 2002-05-06 | Novel 4-anilinoquinoline-3-carboxamides |
CZ20033034A CZ20033034A3 (en) | 2001-05-11 | 2002-05-06 | Novel 4-anilinoquinoline-3-carboxamides |
SK13712003A SK13712003A3 (en) | 2001-05-11 | 2002-05-06 | Novel 4-anilinoquinoline-3-carboxamides |
CA002446717A CA2446717A1 (en) | 2001-05-11 | 2002-05-06 | Novel 4-anilinoquinoline-3-carboxamides |
IL15851702A IL158517A0 (en) | 2001-05-11 | 2002-05-06 | Novel 4-anilinoquinoline-3-carboxamides |
JP2002589457A JP2004533452A (ja) | 2001-05-11 | 2002-05-06 | 新規4−アニリノキノリン−3−カルボキサミド |
KR10-2003-7014579A KR20040007547A (ko) | 2001-05-11 | 2002-05-06 | 신규한 4-아닐리노퀴놀린-3-카르복스아미드 |
RU2003131679/04A RU2281940C2 (ru) | 2001-05-11 | 2002-05-06 | Ароматические производные 6,7-дизамещенных 3-хинолинкарбоксамидов, способ их получения (варианты), фармацевтическая композиция на их основе и их применение для изготовления лекарства |
NZ529302A NZ529302A (en) | 2001-05-11 | 2002-05-06 | Novel 4-anilinoquinoline-3-carboxamides |
US10/477,254 US7037925B2 (en) | 2001-05-11 | 2002-05-06 | 4-anilinoquinoline-3-carboxamides |
PCT/SE2002/000875 WO2002092571A1 (en) | 2001-05-11 | 2002-05-06 | Novel 4-anilinoquinoline-3-carboxamides |
MYPI20021680A MY134136A (en) | 2001-05-11 | 2002-05-09 | Novel compounds comprising jak3 kinase inhibitors |
UA2003109525A UA76142C2 (en) | 2001-05-11 | 2002-06-05 | 4-anilinoquinoline-3-carboxamides and pharmaceutically acceptable salts thereof and pharmaceutical composition containing them |
ZA200308350A ZA200308350B (en) | 2001-05-11 | 2003-10-27 | Novel 4-anilinoquinoline-3-carboxamides. |
IS7016A IS7016A (is) | 2001-05-11 | 2003-11-05 | Ný 4-anilínókínólín-3-karboxamíð |
BG108325A BG108325A (bg) | 2001-05-11 | 2003-11-07 | Нови 4-анилинохинолин-3-карбоксамиди |
NO20034992A NO20034992D0 (no) | 2001-05-11 | 2003-11-10 | Nye 4-aninlinokinolin-3-karboksamider |
US11/368,914 US20060173034A1 (en) | 2001-05-11 | 2006-03-06 | Novel 4-anilinoquinoline-3-carboxamides |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE0101675A SE0101675D0 (sv) | 2001-05-11 | 2001-05-11 | Novel composition |
Publications (1)
Publication Number | Publication Date |
---|---|
SE0101675D0 true SE0101675D0 (sv) | 2001-05-11 |
Family
ID=20284085
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SE0101675A SE0101675D0 (sv) | 2001-05-11 | 2001-05-11 | Novel composition |
Country Status (25)
Country | Link |
---|---|
US (2) | US7037925B2 (sv) |
EP (1) | EP1387830A1 (sv) |
JP (1) | JP2004533452A (sv) |
KR (1) | KR20040007547A (sv) |
CN (1) | CN1286815C (sv) |
AR (1) | AR037489A1 (sv) |
BG (1) | BG108325A (sv) |
BR (1) | BR0209431A (sv) |
CA (1) | CA2446717A1 (sv) |
CZ (1) | CZ20033034A3 (sv) |
EE (1) | EE200300544A (sv) |
HU (1) | HUP0401339A2 (sv) |
IL (1) | IL158517A0 (sv) |
IS (1) | IS7016A (sv) |
MX (1) | MXPA03010207A (sv) |
MY (1) | MY134136A (sv) |
NO (1) | NO20034992D0 (sv) |
NZ (1) | NZ529302A (sv) |
PL (1) | PL366766A1 (sv) |
RU (1) | RU2281940C2 (sv) |
SE (1) | SE0101675D0 (sv) |
SK (1) | SK13712003A3 (sv) |
UA (1) | UA76142C2 (sv) |
WO (1) | WO2002092571A1 (sv) |
ZA (1) | ZA200308350B (sv) |
Families Citing this family (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2003249212C1 (en) | 2002-07-15 | 2011-10-27 | Symphony Evolution, Inc. | Receptor-type kinase modulators and methods of use |
SE0301373D0 (sv) | 2003-05-09 | 2003-05-09 | Astrazeneca Ab | Novel compounds |
TWI328009B (en) | 2003-05-21 | 2010-08-01 | Glaxo Group Ltd | Quinoline derivatives as phosphodiesterase inhibitors |
US7488739B2 (en) | 2003-07-24 | 2009-02-10 | Astellas Pharma Inc. | Quinolone derivative or salt thereof |
EP2213661B1 (en) | 2003-09-26 | 2011-07-20 | Exelixis Inc. | c-Met Modulators and Methods of Use |
GB0322722D0 (en) * | 2003-09-27 | 2003-10-29 | Glaxo Group Ltd | Compounds |
JP2007518823A (ja) * | 2004-01-23 | 2007-07-12 | アムゲン インコーポレイテッド | キノリン、キナゾリン、ピリジン、及びピリミジン化合物と炎症、血管新生、及び癌に対する治療におけるそれら化合物の用途 |
SE0400284D0 (sv) * | 2004-02-10 | 2004-02-10 | Astrazeneca Ab | Novel compounds |
JP2007536310A (ja) * | 2004-05-03 | 2007-12-13 | ノバルティス アクチエンゲゼルシャフト | S1p受容体アゴニストおよびjak3キナーゼ阻害剤を含む、組合せ剤 |
WO2006040520A1 (en) | 2004-10-12 | 2006-04-20 | Astrazeneca Ab | Quinazoline derivatives |
AU2005299018B2 (en) * | 2004-10-19 | 2011-07-07 | F. Hoffmann-La Roche Ag | Quinoline derivatives |
CA2626375A1 (en) | 2005-10-28 | 2007-05-03 | Astrazeneca Ab | 4- (3-aminopyrazole) pyrimidine derivatives for use as tyrosine kinase inhibitors in the treatment of cancer |
US20090076075A1 (en) * | 2006-03-02 | 2009-03-19 | Frederic Henri Jung | Quinoline derivatives |
UY30183A1 (es) * | 2006-03-02 | 2007-10-31 | Astrazeneca Ab | Derivados de quinolina |
PL2383271T3 (pl) | 2006-03-13 | 2013-12-31 | Kyorin Seiyaku Kk | Aminochinolony jako inhibitory GSK-3 |
KR20080112380A (ko) * | 2006-04-14 | 2008-12-24 | 아스트라제네카 아베 | Csf-1r 키나제 억제제로서의 4-아닐리노퀴놀린-3-카르복스아미드 |
WO2007139496A1 (en) * | 2006-05-30 | 2007-12-06 | Clanotech Ab | Quinoline derivatives acting as tyrosine kinase inhibitors |
TW200829555A (en) * | 2006-11-10 | 2008-07-16 | Astrazeneca Ab | Chemical compounds |
CL2008000191A1 (es) * | 2007-01-25 | 2008-08-22 | Astrazeneca Ab | Compuestos derivados de 4-amino-cinnotina-3-carboxamida; inhibidores de csf-1r quinasa; su proceso de preparacion; y su uso para tratar el cancer. |
EP2203458B1 (en) * | 2007-09-11 | 2011-11-02 | Kyorin Pharmaceutical Co., Ltd. | Cyanoaminoquinolones as gsk-3 inhibitors |
US8476261B2 (en) | 2007-09-12 | 2013-07-02 | Kyorin Pharmaceutical Co., Ltd. | Spirocyclic aminoquinolones as GSK-3 inhibitors |
AU2009244897B2 (en) | 2008-04-16 | 2014-11-13 | Alexion Pharmaceuticals, Inc. | 2, 6-diamino- pyrimidin- 5-yl-carboxamides as syk or JAK kinases inhibitors |
US8138339B2 (en) | 2008-04-16 | 2012-03-20 | Portola Pharmaceuticals, Inc. | Inhibitors of protein kinases |
JP2011520804A (ja) * | 2008-05-07 | 2011-07-21 | アストラゼネカ アクチボラグ | 化合物 |
EP2361902A4 (en) * | 2008-11-21 | 2012-04-25 | Astellas Pharma Inc | 4,6-DIAMINONICOTINSÄUREAMIDVERBINDUNG |
TWI641593B (zh) | 2009-01-16 | 2018-11-21 | 美商艾克塞里克斯公司 | 包含n-(4-{〔6,7-雙(甲氧基)喹啉-4-基〕氧基}苯基)-n’-(4-氟苯基)環丙烷-1,1-二甲醯胺之蘋果酸鹽之醫藥組合物及其用途 |
CN102421784B (zh) | 2009-03-11 | 2015-09-30 | 杏林制药株式会社 | 作为gsk-3抑制剂的7-环烷基氨基喹诺酮 |
WO2010129802A1 (en) | 2009-05-06 | 2010-11-11 | Portola Pharmaceuticals, Inc. | Inhibitors of jak |
UA108618C2 (uk) | 2009-08-07 | 2015-05-25 | Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку | |
EP2597955B1 (en) | 2010-07-30 | 2016-01-20 | OncoTherapy Science, Inc. | Quinoline derivatives and melk inhibitors containing the same |
UY33549A (es) * | 2010-08-10 | 2012-01-31 | Glaxo Group Ltd | Quinolil aminas como agentes inhibidores de las quinasas |
TW201300360A (zh) | 2010-11-01 | 2013-01-01 | Portola Pharm Inc | 做為jak激酶調節劑之菸鹼醯胺 |
EP2680844B1 (en) | 2011-03-04 | 2016-10-19 | GlaxoSmithKline Intellectual Property Development Limited | Amino-quinolines as kinase inhibitors |
TWI547494B (zh) | 2011-08-18 | 2016-09-01 | 葛蘭素史克智慧財產發展有限公司 | 作為激酶抑制劑之胺基喹唑啉類 |
SG10201601352UA (en) | 2011-11-23 | 2016-03-30 | Portola Pharm Inc | Pyrazine kinase inhibitors |
TWI592417B (zh) | 2012-09-13 | 2017-07-21 | 葛蘭素史克智慧財產發展有限公司 | 胺基喹唑啉激酶抑制劑之前藥 |
TW201425307A (zh) | 2012-09-13 | 2014-07-01 | Glaxosmithkline Llc | 作為激酶抑制劑之胺基-喹啉類 |
AU2014216178B2 (en) | 2013-02-15 | 2018-06-28 | KALA BIO, Inc. | Therapeutic compounds and uses thereof |
AU2014219024B2 (en) | 2013-02-20 | 2018-04-05 | KALA BIO, Inc. | Therapeutic compounds and uses thereof |
US9688688B2 (en) | 2013-02-20 | 2017-06-27 | Kala Pharmaceuticals, Inc. | Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof |
RU2662810C2 (ru) | 2013-02-21 | 2018-07-31 | Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед | Хиназолины в качестве ингибиторов киназы |
US9890173B2 (en) | 2013-11-01 | 2018-02-13 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
MX355330B (es) | 2013-11-01 | 2018-04-16 | Kala Pharmaceuticals Inc | Formas cristalinas de compuestos terapeuticos y sus usos. |
WO2016125187A1 (en) * | 2015-02-03 | 2016-08-11 | Council Of Scientific & Industrial Research | Novel quinoline derivatives and preparation thereof |
EP3509421A4 (en) | 2016-09-08 | 2020-05-20 | Kala Pharmaceuticals, Inc. | CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF |
AU2017324716B2 (en) | 2016-09-08 | 2020-08-13 | KALA BIO, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
EP3509422A4 (en) | 2016-09-08 | 2020-05-20 | Kala Pharmaceuticals, Inc. | CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF |
SG11201903463PA (en) * | 2016-10-18 | 2019-05-30 | Beijing Konruns Pharmaceutical Co Ltd | Quinolyl-substituted carboxylic acid compound or pharmaceutically acceptable salt thereof, pharmaceutical composition of the same, and use of the same |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3037925A (en) * | 1958-04-09 | 1962-06-05 | Smith Corp A O | Cathodically protected structure and method of making same |
UA73073C2 (uk) | 1997-04-03 | 2005-06-15 | Уайт Холдінгз Корпорейшн | Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція |
HUP0103386A3 (en) * | 1998-08-21 | 2002-07-29 | Parker Hughes Inst St Paul | Use of quinazoline derivatives for producing pharmaceutical compositions having jak 3-inhibitor effect |
-
2001
- 2001-05-11 SE SE0101675A patent/SE0101675D0/sv unknown
-
2002
- 2002-05-03 AR ARP020101633A patent/AR037489A1/es not_active Application Discontinuation
- 2002-05-06 US US10/477,254 patent/US7037925B2/en not_active Expired - Fee Related
- 2002-05-06 PL PL02366766A patent/PL366766A1/xx unknown
- 2002-05-06 EE EEP200300544A patent/EE200300544A/xx unknown
- 2002-05-06 JP JP2002589457A patent/JP2004533452A/ja active Pending
- 2002-05-06 MX MXPA03010207A patent/MXPA03010207A/es unknown
- 2002-05-06 SK SK13712003A patent/SK13712003A3/sk unknown
- 2002-05-06 BR BR0209431-2A patent/BR0209431A/pt not_active IP Right Cessation
- 2002-05-06 NZ NZ529302A patent/NZ529302A/en unknown
- 2002-05-06 CA CA002446717A patent/CA2446717A1/en not_active Abandoned
- 2002-05-06 WO PCT/SE2002/000875 patent/WO2002092571A1/en active IP Right Grant
- 2002-05-06 RU RU2003131679/04A patent/RU2281940C2/ru not_active IP Right Cessation
- 2002-05-06 EP EP02733657A patent/EP1387830A1/en not_active Withdrawn
- 2002-05-06 HU HU0401339A patent/HUP0401339A2/hu unknown
- 2002-05-06 KR KR10-2003-7014579A patent/KR20040007547A/ko not_active Application Discontinuation
- 2002-05-06 CN CNB02809722XA patent/CN1286815C/zh not_active Expired - Fee Related
- 2002-05-06 CZ CZ20033034A patent/CZ20033034A3/cs unknown
- 2002-05-06 IL IL15851702A patent/IL158517A0/xx unknown
- 2002-05-09 MY MYPI20021680A patent/MY134136A/en unknown
- 2002-06-05 UA UA2003109525A patent/UA76142C2/uk unknown
-
2003
- 2003-10-27 ZA ZA200308350A patent/ZA200308350B/en unknown
- 2003-11-05 IS IS7016A patent/IS7016A/is unknown
- 2003-11-07 BG BG108325A patent/BG108325A/bg unknown
- 2003-11-10 NO NO20034992A patent/NO20034992D0/no not_active Application Discontinuation
-
2006
- 2006-03-06 US US11/368,914 patent/US20060173034A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AR037489A1 (es) | 2004-11-17 |
IL158517A0 (en) | 2004-05-12 |
HUP0401339A2 (hu) | 2004-12-28 |
IS7016A (is) | 2003-11-05 |
ZA200308350B (en) | 2005-01-27 |
SK13712003A3 (en) | 2004-10-05 |
JP2004533452A (ja) | 2004-11-04 |
CN1507434A (zh) | 2004-06-23 |
EE200300544A (et) | 2004-02-16 |
PL366766A1 (en) | 2005-02-07 |
UA76142C2 (en) | 2006-07-17 |
CA2446717A1 (en) | 2002-11-21 |
US20060173034A1 (en) | 2006-08-03 |
NZ529302A (en) | 2004-08-27 |
BR0209431A (pt) | 2004-08-03 |
MXPA03010207A (es) | 2004-03-10 |
NO20034992D0 (no) | 2003-11-10 |
RU2281940C2 (ru) | 2006-08-20 |
HU0401339D0 (en) | 2004-08-30 |
MY134136A (en) | 2007-11-30 |
US20040248923A1 (en) | 2004-12-09 |
US7037925B2 (en) | 2006-05-02 |
EP1387830A1 (en) | 2004-02-11 |
CZ20033034A3 (en) | 2004-06-16 |
RU2003131679A (ru) | 2005-05-10 |
WO2002092571A1 (en) | 2002-11-21 |
CN1286815C (zh) | 2006-11-29 |
KR20040007547A (ko) | 2004-01-24 |
BG108325A (bg) | 2004-11-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SE0101675D0 (sv) | Novel composition | |
SE0301372D0 (sv) | Novel compounds | |
MXPA05012025A (es) | Imidazo y tiazolopiridinas como inhibidores de cinasa jak3. | |
ATE430747T1 (de) | 2-pyrimidinyl-pyrazolopyridin-erbb- kinaseinhibitoren | |
UA86591C2 (ru) | Пирролодигидроизохинолины как ингибиторы pde10, фармацевтическая композиция на их основе | |
ATE433447T1 (de) | Pyrimiidinverbindungen | |
IL160915A0 (en) | Indolizines inhibiting kinase proteins | |
AU3652102A (en) | Compounds and their uses | |
UA91002C2 (ru) | 7-фенилалкилзамещенные 2-хинолиноны и 2-хиноксалиноны как ингибиторы поле(адф-рибоза)полимеразы | |
SE0301700D0 (sv) | Novel compounds | |
MXPA03001982A (es) | Amino-aza-cicloalcanos sustituidos utiles contra la malaria. | |
CY1109006T1 (el) | Παραγωγα πουρινης ως αναστολεις κινασης | |
SE0400284D0 (sv) | Novel compounds | |
ATE413388T1 (de) | Muskarin antagonisten | |
SE0302139D0 (sv) | Novel compounds | |
DK1456212T3 (da) | 6-aminomorphinanderivater, fremgangsmåder til fremstilling heraf og disses anvendelse | |
NO20063293L (no) | Farmasoytiske forbindelser | |
BR0318521A (pt) | arilindenopiridinas e arilindenopirimidinas e métodos terapêuticos e profiláticos relacionados | |
RS79703A (en) | Phenyl heterocyclyl ether derivatives as serotonin re-uptake inhibitors | |
DE60201074D1 (en) | Pyrazolopyridinderivate | |
MXPA03010259A (es) | Nuevos derivados de 5-tio-ss-d-xilopiranosida, procedimiento de preparacion, composiciones farmaceuticas que los contienen y el uso terapeutico de los mismos. | |
UY27311A1 (es) | Agentes antibacterianos | |
MXPA05011430A (es) | Compuestos lineares basicos antagonistas de nk-2 y formulaciones que los contienen. | |
WO2005019224A3 (en) | Novel antiinfective compounds |